RxDoctor Payments Data

Darlene Jones, DO

Physical Medicine & Rehabilitation · Florence, SCNPI 1184771891

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 32 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Scilex Pharmaceuticals Inc. at 54.9% of the total. Reporting peaked in 2024 at $204 and has fallen 90.9% since, to $19 in 2025.

$571in general payments, 2019–2025

Across 32 payments — averaging $17.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Scilex Pharmaceuticals Inc.$314
  • Forte Bio-pharma LLC$103
  • AbbVie$47
  • Boston Scientific$35
  • Collegium Pharmaceutical, Inc.$28
  • Protega Pharmaceutials Inc$27
  • plus $18 from 1 others

What the payments were for

  • Food & beverage$571100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Scilex Pharmaceuticals Inc.18$314
Forte Bio-pharma LLC5$103
AbbVie(2 entities)2$47
Boston Scientific2$35
Collegium Pharmaceutical, Inc.2$28
Protega Pharmaceutials Inc2$27
Galderma Laboratories, L.p.1$18

How this compares

$571 in reported general payments places this provider in the 70th percentile of 122 physical medicine & rehabilitation providers in South Carolina.

See all physical medicine & rehabilitation providers in South Carolina

Medicare billing

Part B allowed, 2024
$2,610
Medicare patients
36
Services billed
71

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen168$11,314
BelbucaBuprenorphine Hcl16$9,548
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen178$4,213
Buprenorphine15$3,893
Gabapentin222$2,356
Lidocaine22$1,481
Diclofenac Sodium44$1,443
Naloxone Hcl18$1,014
Pregabalin48$619
Duloxetine Hcl55$539
Buprenorphine Hcl37$524
Tizanidine Hcl68$489
Oxycodone Hcl29$364
Baclofen36$280
Methocarbamol17$241

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$28$9,54816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 122 physical medicine & rehabilitation providers in South Carolina.

Other physical medicine & rehabilitation in Florence

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →